ArticleCancer immunology, immunotherapy : CII2018

The BCR-ABL inhibitor nilotinib influences phenotype and function of monocyte-derived human dendritic cells.

Daniela Dörfel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.